How I Treat Neuroendocrine Tumors

Aasems Jacob¹ Gaby Gabriel²,³ Robert A. Ramirez⁴ Yi-Zarn Wang⁵ Lowell Anthony¹,³ Aman Chauhan¹,³

¹Division of Medical Oncology, University of Kentucky, Lexington, Kentucky, United States
²Department of Radiology, Division of Interventional Radiology, University of Kentucky, Lexington, Kentucky, United States
³Division of Medical Oncology, Markey Cancer Center, University of Kentucky, Lexington, Kentucky, United States
⁴Department of Hematology and Oncology, Ochsner Health New Orleans, New Orleans, Louisiana, United States
⁵Department of Surgery, Louisiana State University Health Science Center, New Orleans, Louisiana, United States

Address for correspondence Aman Chauhan, MD, Department of Medical Oncology, University of Kentucky, 800 Rose Street, Lexington 40536, United States (e-mail: amanchauhan@uky.edu).

Introduction

Neuroendocrine tumors (NETs) originate from diffuse neuroendocrine cell system and can develop in many organs. Gastroenteropancreatic (GEP) NETs account for approximately 70%, followed by bronchopulmonary and thymic NETs.¹ The World Health Organization (WHO) classification divides GEP NETs into well-differentiated NETs and poorly differentiated neuroendocrine carcinoma (NEC). Well-differentiated NETs can be grade 1 (G1; mitotic count < 2 per 10 HPF - high power field, Ki-67 < 3%), G2 (mitotic count: 2–20, Ki-67: 3–20%) tumors, and G3 (mitotic count > 20, Ki-67 > 20%).² Poorly differentiated NECs are always G3 tumors with >20 mitotic count and Ki-67 index >20% and include small- and large-cell NECs.² A total of 10 to 13% of NETs do not have a primary site identified at the time of diagnosis and are called NETs of unknown primary.¹,³ NETs can also be differentiated based on the secretion of vasoactive amines and hormones into functional (30%) and nonfunctional NETs (70%).¹ This article focuses on the management of well-differentiated NETs with attention to systemic therapy. Factors influencing initial medical decision-making in NET management include functional status, stage, and grade, burden of metastatic disease, and symptoms at presentation.

Case 1

A 61-year-old female presented with right hip pain, diarrhea, and weight loss over the past few months. Pelvic X-ray showed lytic lesions in right femoral acetabulum. Computerized tomography (CT) of abdomen showed multiple liver lesions and additional bony metastasis in ribs. Biopsy of a liver lesion showed a metastatic G2 well-differentiated NET with KI-67 of 10%.

Diagnosis

CT and/or magnetic resonance (MR) scans are the commonly utilized imaging modalities for initial evaluation. Multiphasic CT/MRI is helpful in evaluating liver metastasis since NETs are highly vascular and can appear isodense on conventional scans. NETs with unknown primary site should be additionally evaluated with upper and lower endoscopy with attention to the terminal ileum or by CT enterography. Evaluation with somatostatin receptor (SSR)-based imaging, like 68-Ga-DOTATATE positron emission tomography (PET), or Cu-64-DOTATATE (preferred over Indium-111-pentetreotide SPECT), is utilized to assess receptor status for determining benefit of SSR-directed therapy and evaluate suspected metastasis if unclear on initial imaging.


© 2021. Indian Society of Medical and Paediatric Oncology. All rights reserved.

This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd., A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
When symptoms are suggestive of carcinoid syndrome (unclear in this case), the initial biochemical evaluation of choice is 24-hour urinary excretion of 5-hydroxyindoleacetic acid (5-HIAA). The test has 90% sensitivity and 90% specificity to detect carcinoid syndrome.\(^4\) Urinary 5-HIAA level in carcinoid syndrome was found to range between 99 and 2,070 µg/day; however, lower levels may be present with foregut and hindgut tumors. Chromogranin and serotonin levels lack sensitivity and specificity; however, it is useful in foregut, rectal, and pancreatic NETs where 5-HIAA level is not usually elevated.\(^5\) Plasma 5-HIAA level has not been well validated. Serum VIP (VIPoma), glucagon (glucagonoma), gastrin (gastrinoma), and insulin/pro-insulin/C-peptide (insulinoma) levels are helpful in functional pancreatic NETs. ... 24-hour urine 5-HIAA level was 928 µg/day. While awaiting further workup, what treatment should be given for her symptomatic disease?

**Management of Symptoms of Hormone Secretion**

The most common symptoms from functional NETs are flushing and diarrhea and are associated with elevated urinary 5-HIAA. Since 80% of well-differentiated gastrointestinal (GI)-NETs express SSR, somatostatin analogs (SSA)-like octreotide and lanreotide are highly effective in controlling the symptoms. Initial therapy should be with octreotide of 50 to 750 µg/day, two to four times a day subcutaneously (typically started at 100–150 µg thrice a day with some patients requiring up to 1,500 µg/day, although data limited). This not only provides rapid symptom relief but also acts as test dose before initiating long-acting depot. After 1 to 2 weeks on short-acting SSA confirming symptomatic relief and absence of adverse reactions, we initiate long-acting depot injections starting with Octreotide intramuscular (IM) depot injection (octreotide long acting release - LAR) 20 to 30 mg at every 4 weeks. Although dose can be decreased to 10-mg IM at every 2 weeks depending on the response, in our practice, we start at 30-mg IM every 4 weeks day and usually do not deescalate due to its benefit in tumor stabilization as seen in PROMID randomized clinical trial.\(^6\) Continue short-acting SSA for the first 2 weeks to maintain therapeutic levels. Temporary exacerbation of symptoms can be treated with additional subcutaneous injections. Lanreotide given 120-mg subcutaneous at every 4 weeks has similar efficacy and tolerance with additional progression-free survival (PFS) benefit and carcinoid syndrome control as noted in CLARINET and ELECT studies.\(^7\) Phase-II randomized trials have not shown benefit of adding pasireotide, a second-generation SSA along to everolimus.\(^8,9\)

Telotristat ethyl, a serotonin synthesis inhibitor is Food and Drug Administration (FDA)-approved for the management of carcinoid syndrome diarrhea refractory to SSA and is usually very well tolerated.\(^10\) Low-dose interferon alfa can improve symptoms in patients refractory to SSA.\(^11\) However, the treatment is rarely used due to its high toxicity profile of fatigue, depression, and flu-like symptoms. Antidiarrheal therapy with loperamide and/or diphenoxylate-atropine should also be considered. Reducing the SSA intervals, and increasing the dose may offer some benefit.

Initial therapy for insulinomas is carbohydrates and diazoxide which inhibit hormone release. For gastrinomas, oral proton pump inhibitors should be considered. SSA can be used in all refractory disease.\(^12\) ... CT chest showed no disease. Upper and lower GI endoscopic evaluation was unremarkable. What is the initial treatment for this patient?

**Treatment**

Surgery remains the mainstay for local or locoregional resectable NETs. With selective low surgical risk patients, early surgical exploration can be considered even in the setting of unknown primary.\(^13\) There is no clear role of adjuvant radiation or chemotherapy and observation is the preferred approach. Surgical resection can also be considered in metastatic disease with refractory symptoms from hormone secretion. Resection of an asymptomatic primary site in the setting of unresectable metastases is generally not recommended.\(^14\)

For low-volume and asymptomatic unresectable disease, watchful waiting until symptomatic disease or radiological progression is reasonable and acceptable. Consider CT scan in 3 to 4 months to assess tumor growth rate. Low-grade well-differentiated NETs with very low burden of metastatic disease which is stable on the repeat scan can be watched closely without initiating further systemic therapy and extending the scanning interval to 6 months. However, in symptomatic, functional, moderate-to-high-volume tumors, or tumors with documented radiological growth, treatment initiation should be considered.

SSAs have also been found to provide disease stabilization and PFS benefit.\(^6,7\) These should be considered as first-line therapy due to their favorable side-effect profile and proven benefit in randomized controlled trials. GETNE-TRASGU nomograms could be used to estimate PFS in patient receiving SSA based on other factors, like tumor location, Ki-67 index, and symptoms; however, it is not widely used in the United States.\(^15\) Benefit of lanreotide and octreotide LAR in advanced well-differentiated nonfunctioning GEP NET was shown in randomized controlled trials (RCTs).\(^16\) Table 1 summarizes some key clinical trials in NETs.

... Monthly octreotide LAR was initiated with symptomatic improvement. CT scan after 4 months showed disease progression in liver and new right upper quadrant abdominal pain and worsening right hip pain. What are the treatment options for this patient now?

Liver predominant metastatic disease can be managed with surgical resection, liver transplant, or nonsurgical liver-directed therapies like ablation and embolotheapies. If liver function is adequate and with the feature of a few dominated large liver metastasis in the absence of diffuse involvement of both liver lobes, surgical resection is an option with the goal of a 70% cytoreduction. This can offer symptom relief and lower rate of disease recurrence.\(^17\) Nonsurgical procedures like radiofrequency ablation, cryoablation, or microwave ablation can be utilized for oligometastatic liver disease or as an adjunct to surgery. Data for external beam radiation in well-differentiated NETs is limited and is often not used in
## Table 1 Trials evaluating efficacy of treatments for NETs

<table>
<thead>
<tr>
<th>Drug</th>
<th>Indication</th>
<th>Trial</th>
<th>Comparison</th>
<th>OS</th>
<th>PFS</th>
<th>Comments (reference)</th>
<th>MCBS score&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Octreotide (LAR 30-mg IM q28d)</td>
<td>Midgut or UP NF G1, G2 NET</td>
<td>PROMID, phase III</td>
<td>Placebo</td>
<td>84.7 vs. 83.7 mo (HR: 0.47, p = NS, 0.03–0.59)</td>
<td>14.3 vs. 6 mo (HR: 0.20, 95% CI: 0.18–0.22)</td>
<td>84.7 vs. 83.7 mo (p = NS, 0.03–0.59)</td>
<td>3, 59% patients had stable disease for 3–6 mo prior to enrollment, PFS &amp; OS estimate 33 mo, No QoL benefit</td>
</tr>
<tr>
<td>Lanreotide (120-mg deep sc q28d)</td>
<td>Midgut, pancreatic or UP NF NET &lt;10%, G1 or 2, SSTR+</td>
<td>CLARINET, phase III</td>
<td>Placebo &amp; lanreotide</td>
<td>NR vs. 18 mo (HR: 0.47, 95% CI: 0.30–0.59)</td>
<td>14.6 vs. 11.3 m (HR: 0.59, 95% CI: 0.09–1.10)</td>
<td>No mature data</td>
<td>76% patients had stable disease for 3–4 mo after enrollment, 39% patients had stable disease for 3–6 mo prior to enrollment, PFS estimate 23 mo</td>
</tr>
<tr>
<td>Everolimus + octreotide</td>
<td>Advanced G1, G2 NET</td>
<td>RADIANT-1, phase III</td>
<td>Placebo + octreotide</td>
<td>11.4 vs. 5.5 mo (HR: 0.49, 95% CI: 0.26–0.70)</td>
<td>12.5 mo PFS gain</td>
<td>No QoL data</td>
<td>11.8 mo PFS gain</td>
</tr>
<tr>
<td>Sunitinib</td>
<td>Advanced G1, G2 NET</td>
<td>Phase III</td>
<td>Placebo &amp; sunitinib</td>
<td>11.4 vs. 11.8 m (HR: 0.70, 95% CI: 0.45–1.0)</td>
<td>11.8 mo PFS gain</td>
<td>No QoL data</td>
<td>11.4 vs. 11.8 m (HR: 0.70, 95% CI: 0.45–1.0)</td>
</tr>
<tr>
<td>Everolimus + bevacizumab</td>
<td>Midgut, pancreatic or UP NF NET &lt;10%, G1 or 2, SSTR+</td>
<td>ALLIANCE A021202, phase III</td>
<td>Placebo</td>
<td>16.8 vs. 15.4 m (HR: 0.69, 95% CI: 0.52–0.90)</td>
<td>16.8 vs. 15.4 m (HR: 0.69, 95% CI: 0.52–0.90)</td>
<td>No difference at 22.6 mo</td>
<td>16.8 vs. 15.4 m (HR: 0.69, 95% CI: 0.52–0.90)</td>
</tr>
<tr>
<td>Pazopanib</td>
<td>Well-differentiated pancreatic NET</td>
<td>COOPERATE-2, phase II</td>
<td>Placebo</td>
<td>16.8 vs. 16.6 m (HR: 0.69, 95% CI: 0.52–0.90)</td>
<td>11.8 vs. 15.4 m (HR: 0.69, 95% CI: 0.52–0.90)</td>
<td>No different at 22.6 mo</td>
<td>16.8 vs. 15.4 m (HR: 0.69, 95% CI: 0.52–0.90)</td>
</tr>
<tr>
<td>Everolimus + pasireotide</td>
<td>Lung and thymus carcinoids, PD</td>
<td>LUNA, phase II</td>
<td>Everolimus</td>
<td>12.5 vs. 11.8 mo (HR: 0.80, 95% CI: 0.60–1.0)</td>
<td>12.5 vs. 11.8 mo (HR: 0.80, 95% CI: 0.60–1.0)</td>
<td>No QoL data</td>
<td>12.5 vs. 11.8 mo (HR: 0.80, 95% CI: 0.60–1.0)</td>
</tr>
<tr>
<td>Pazopanib + everolimus</td>
<td>Well-differentiated non-pancreatic NET</td>
<td>COOPERATE-2, phase II</td>
<td>Everolimus</td>
<td>16.8 vs. 16.6 m (HR: 0.69, 95% CI: 0.52–0.90)</td>
<td>16.8 vs. 16.6 m (HR: 0.69, 95% CI: 0.52–0.90)</td>
<td>No different at 22.6 mo</td>
<td>16.8 vs. 16.6 m (HR: 0.69, 95% CI: 0.52–0.90)</td>
</tr>
<tr>
<td>Everolimus + pasireotide</td>
<td>Lung and thymus carcinoids, PD</td>
<td>LUNA, phase II</td>
<td>Pasireotide</td>
<td>12.5 vs. 11.8 mo (HR: 0.80, 95% CI: 0.60–1.0)</td>
<td>12.5 vs. 11.8 mo (HR: 0.80, 95% CI: 0.60–1.0)</td>
<td>No QoL data</td>
<td>14.9 vs. 11.8 mo (HR: 0.80, 95% CI: 0.60–1.0)</td>
</tr>
<tr>
<td>Pasireotide + everolimus</td>
<td>Well-differentiated pancreatic NET</td>
<td>COOPERATE-2, phase II</td>
<td>Everolimus</td>
<td>16.8 vs. 16.6 m (HR: 0.69, 95% CI: 0.52–0.90)</td>
<td>16.8 vs. 16.6 m (HR: 0.69, 95% CI: 0.52–0.90)</td>
<td>No different at 22.6 mo</td>
<td>16.8 vs. 16.6 m (HR: 0.69, 95% CI: 0.52–0.90)</td>
</tr>
<tr>
<td>Pasireotide + everolimus</td>
<td>Well-differentiated non-pancreatic NET</td>
<td>COOPERATE-2, phase II</td>
<td>Everolimus</td>
<td>16.8 vs. 16.6 m (HR: 0.69, 95% CI: 0.52–0.90)</td>
<td>16.8 vs. 16.6 m (HR: 0.69, 95% CI: 0.52–0.90)</td>
<td>No different at 22.6 mo</td>
<td>16.8 vs. 16.6 m (HR: 0.69, 95% CI: 0.52–0.90)</td>
</tr>
<tr>
<td>Pasireotide + everolimus</td>
<td>Well-differentiated non-pancreatic NET</td>
<td>COOPERATE-2, phase II</td>
<td>Everolimus</td>
<td>16.8 vs. 16.6 m (HR: 0.69, 95% CI: 0.52–0.90)</td>
<td>16.8 vs. 16.6 m (HR: 0.69, 95% CI: 0.52–0.90)</td>
<td>No different at 22.6 mo</td>
<td>16.8 vs. 16.6 m (HR: 0.69, 95% CI: 0.52–0.90)</td>
</tr>
<tr>
<td>Pazopanib</td>
<td>Well-differentiated non-pancreatic NET</td>
<td>COOPERATE-2, phase II</td>
<td>Everolimus</td>
<td>16.8 vs. 16.6 m (HR: 0.69, 95% CI: 0.52–0.90)</td>
<td>16.8 vs. 16.6 m (HR: 0.69, 95% CI: 0.52–0.90)</td>
<td>No different at 22.6 mo</td>
<td>16.8 vs. 16.6 m (HR: 0.69, 95% CI: 0.52–0.90)</td>
</tr>
<tr>
<td>Pazopanib</td>
<td>Well-differentiated non-pancreatic NET</td>
<td>COOPERATE-2, phase II</td>
<td>Everolimus</td>
<td>16.8 vs. 16.6 m (HR: 0.69, 95% CI: 0.52–0.90)</td>
<td>16.8 vs. 16.6 m (HR: 0.69, 95% CI: 0.52–0.90)</td>
<td>No different at 22.6 mo</td>
<td>16.8 vs. 16.6 m (HR: 0.69, 95% CI: 0.52–0.90)</td>
</tr>
<tr>
<td>Pazopanib</td>
<td>Well-differentiated non-pancreatic NET</td>
<td>COOPERATE-2, phase II</td>
<td>Everolimus</td>
<td>16.8 vs. 16.6 m (HR: 0.69, 95% CI: 0.52–0.90)</td>
<td>16.8 vs. 16.6 m (HR: 0.69, 95% CI: 0.52–0.90)</td>
<td>No different at 22.6 mo</td>
<td>16.8 vs. 16.6 m (HR: 0.69, 95% CI: 0.52–0.90)</td>
</tr>
<tr>
<td>Pazopanib</td>
<td>Well-differentiated non-pancreatic NET</td>
<td>COOPERATE-2, phase II</td>
<td>Everolimus</td>
<td>16.8 vs. 16.6 m (HR: 0.69, 95% CI: 0.52–0.90)</td>
<td>16.8 vs. 16.6 m (HR: 0.69, 95% CI: 0.52–0.90)</td>
<td>No different at 22.6 mo</td>
<td>16.8 vs. 16.6 m (HR: 0.69, 95% CI: 0.52–0.90)</td>
</tr>
<tr>
<td>Pazopanib</td>
<td>Well-differentiated non-pancreatic NET</td>
<td>COOPERATE-2, phase II</td>
<td>Everolimus</td>
<td>16.8 vs. 16.6 m (HR: 0.69, 95% CI: 0.52–0.90)</td>
<td>16.8 vs. 16.6 m (HR: 0.69, 95% CI: 0.52–0.90)</td>
<td>No different at 22.6 mo</td>
<td>16.8 vs. 16.6 m (HR: 0.69, 95% CI: 0.52–0.90)</td>
</tr>
</tbody>
</table>

<sup>a</sup>ESMO–MCBC is a tool assessing clinical benefit of treatment based on trial outcomes with positive points for improved QoL and negative points for poor tolerability.
clinical practice. Percutaneous ablative techniques are limited to lesions typically less than 3 cm in size and generally up to four lesions. However, evidence regarding this is supported only by small case studies.\textsuperscript{18,19} Symptomatic or progressive hepatic predominant unresectable disease can also be treated with bland hepatic arterial embolization, chemoembolization or radioembolization or may be considered as a palliative measure. Transarterial bland embolization (our preferred method) is most commonly performed using bland microspheres (\textit{\textsuperscript{\textbf{Fig. 1}}}). Transarterial chemoembolization follows the same principles as bland embolization with the addition of a chemotherapeutic agent.\textsuperscript{20} Radioembolization involves injection of microspheres incorporating the radioisotope Yttrium-90 intra-arterially into the liver.\textsuperscript{21} Although liver transplantation may provide long-term recurrence-free survival in some patients, the majority ultimately develop recurrent disease.\textsuperscript{22}

... She underwent right and left lobe liver bland embolization without complication. Also received palliative radiation therapy to the right hip. What systemic therapy is ideal now?

**Progression**

In functional NETs, SSAs may be continued for symptom management. Systemic therapy options on progression include everolimus, sunitinib, or Lu-DOTATATE radionuclide therapy (\textit{\textsuperscript{\textbf{Table 1}}}).

Everolimus improves PFS without overall survival (OS) benefit in advanced nonfunctional GI and lung NETs. Grade 1/2 skin, GI side effects, and fatigue were mainly reported.\textsuperscript{23} In advanced G1/2 NETs, treatment with octreotide plus everolimus showed clinically meaningful prolongation of PFS but only trended toward statistical significance.\textsuperscript{24} An open-label extension of the study failed to show any OS benefit as many patients received everolimus off-study.\textsuperscript{25} In our experience, everolimus is active in NETs and is able to stabilize disease in most patients for several months. Oral mucositis can be prevented with prophylactic steroid mouth wash, especially during first 4 to 6 weeks of therapy and dose adjustments are often required.

**Peptide receptor radionuclide therapy:** The evidence of PFS benefit from radiolabeled SSA, Lu-DOTATATE was demonstrated in NETTER-1 trial with an interim analysis, also demonstrating OS benefit.\textsuperscript{26} Objective response rate was higher among patients on peptide receptor radionuclide therapy PRRT (18 vs. 3%). The most common side effect was nausea (59%) from the amino acid infusions administered during treatment for renal protection. Mild cytopenias were also common with nadir counts expected around 4 to 6 weeks after infusion and resolved by 8 weeks.\textsuperscript{27} Later studies also showed improved quality of life.\textsuperscript{28} Patients with G1/2 inoperable and metastatic SSR + NET, with expected survival of >3 months, Karnofsky’s performance status >50, sufficient bone marrow reserve, and creatinine clearance >50 mL/min were included in the clinical trial and should be the ideal candidates for this treatment. The Lu-DOTATATE is acceptable as second- or third-line treatment option for metastatic progressive midgut and pancreatic NET with SSR expression, although pancreatic NETs were not studied in NETTER-1 phase-III clinical trial.\textsuperscript{28} In our practice, we often consider\textsuperscript{177}Lu-DOTATATE as second line if patient has symptomatic disease, bone metastasis, or need for cytoreduction. Lu-DOTATATE has the most superior PFS and overall recurrence rate (ORR) data among the approved therapies for NETs. It can be potentially deferred to third- or fourth-line treatment option in patients with mesenteric disease, as PRRT often does not work well for peritoneal metastasis and in young patients due to concern for long-term myelotoxicity and less than 5% long-term risk of myelodysplasias or leukemia.\textsuperscript{29}

The presence of SSR can be determined by diagnostic imaging using a radiolabeled SSA Indium-111 pentetreotide (Octreoscan) or PET scan using Gallium-68 DOTATATE. The higher sensitivity of the later one makes it the preferred option, especially in patients with low tumor volume. Uptake of radiolabeled isotope is predictive of response to therapy.

\textbf{Fig. 1} (A) Celiac artery angiogram demonstrating multiple enhancing metastatic NET throughout the liver. (B) Left hepatic artery angiogram demonstrating enhancing metastatic NET in the left lobe of the liver (representative images; source: Department of Radiology, University of Kentucky). NET, neuroendocrine tumors.
Tyrosine kinase inhibitors: Although sunitinib, sorafenib, surufatinib, pazopanib, lenvatinib, and cabozantinib have been evaluated in advanced GI-NET in phase-2 and -3 trials, only sunitinib is currently FDA approved for metastatic progressive pancreatic NETs.\(^{30-32}\) In lung and GI-NETs, pazopanib showed PFS improvement compared with placebo without OS benefit. Nintedanib, was evaluated in a phase-2 trial for G1/2 NET and was associated with disease stabilization and delayed deterioration of quality of life.\(^{33}\)

Bevacizumab had a PFS benefit when given with octreotide compared to interferon alfa in a phase-II trial.\(^{34}\) However, the confirmatory larger randomized trial with 427 patients failed to show any PFS benefit.\(^{35}\) We do not recommend use of bevacizumab in the management of NETs.

Interferon alfa (IFNa) is recommended only if other treatment options are unavailable due to the relatively low level of evidence of benefit and significant side-effect profile.\(^{36,37}\) Low-dose IFNa can reduce symptoms of hormonal hypersecretion and result in tumor stabilization in some patients, but tumor regression is rare.\(^{34,38,39}\) IFNa is dosed at 3 to 5 MU/kg three times weekly and dose should be titrated to a leukocyte count of 3,000/\(\mu\)L. Pegylated IFN (80–150 \(\mu\)g per week subcutaneous) has better tolerability compared with IFNa.

Cytotoxic chemotherapy (\(\Rightarrow\) Table 2) should be considered in patients with progressive metastatic disease with no standard approved treatment options. Regimens that have shown evidence of activity include capectabine plus temozolomide (CAPTEM) and short-term infusional 5 FU with leucovorin plus oxaliplatin (FOLFOX); however, confirmatory studies are needed.\(^{40,41}\) Based on emerging data and toxicity profile, we consider CAPTEM as the initial chemotherapy regimen especially for G2/3 well-differentiated midgut and pancreatic NET after progression on other treatments. The poor PFS from Eastern Cooperative Oncology Group (ECOG) E1281 trial and toxicity of the drugs have questioned the use of 5 FU, streptozocin, and doxorubicin in the treatment of NET.\(^{42}\)

Immunotherapy: Data on use of immune checkpoint inhibitors are early but promising (\(\Rightarrow\) Table 2). Patients with microsatellite unstable tumors and tumor mutational burden \(\geq 10\) can now receive pembrolizumab based on available evidence.\(^{43}\) DART SWOG 1609 phase-II trial was a basket trial evaluating dual anti-CTLA4 and anti-programmed death 1 (PD1) blockers in rare tumors which showed response mainly in high grade NET. Among the 14 patients with G1/2 NET, 2 had stable disease lasting \(\geq 6\) months.

### Table 2: Cytotoxic chemotherapy and immunotherapy regimens studied in NETs

<table>
<thead>
<tr>
<th>Regimen</th>
<th>Trial (year)</th>
<th>n</th>
<th>CR (%)</th>
<th>PR (%)</th>
<th>SD (%)</th>
<th>mPFS (mo)</th>
<th>mOS (mo)</th>
<th>Comments (ref.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Capecitabine</td>
<td>Phase II (2011)</td>
<td>19</td>
<td>–</td>
<td>–</td>
<td>68</td>
<td>9.9</td>
<td>36.5</td>
<td>54</td>
</tr>
<tr>
<td>Capecitabine + oxaliplatin</td>
<td>Phase II (2007)</td>
<td>27</td>
<td>–</td>
<td>30</td>
<td>48</td>
<td>18</td>
<td>32</td>
<td>55</td>
</tr>
<tr>
<td>Capecitabine + Bev</td>
<td>Phase II (2014)</td>
<td>49</td>
<td>–</td>
<td>18</td>
<td>70</td>
<td>23.4</td>
<td>NR</td>
<td>2-year OS: 85%; 82% ileal primary</td>
</tr>
<tr>
<td>5 FU + streptozocin</td>
<td>Phase II/III ECOG E1281 (2005)</td>
<td>78/85</td>
<td>2.4</td>
<td>16</td>
<td>13.5</td>
<td>8</td>
<td>15.4</td>
<td>15.4</td>
</tr>
<tr>
<td>FOLFOX + Bev</td>
<td>Phase II (2016)</td>
<td>36/40</td>
<td>–</td>
<td>25</td>
<td>18</td>
<td>69.4</td>
<td>60</td>
<td>21</td>
</tr>
<tr>
<td>TMZ</td>
<td>Retrospective (2007)</td>
<td>36</td>
<td>–</td>
<td>14</td>
<td>53</td>
<td>7</td>
<td>16</td>
<td>57</td>
</tr>
<tr>
<td>CAPEOX + Bev</td>
<td>Retrospective (2013)</td>
<td>31</td>
<td>–</td>
<td>14</td>
<td>52</td>
<td>5</td>
<td>23.2</td>
<td>Only bronchial carcinoids</td>
</tr>
<tr>
<td>Capecitabine + TMZ</td>
<td>Retrospective (2013)</td>
<td>18</td>
<td>5.5</td>
<td>55.5</td>
<td>22.2</td>
<td>14</td>
<td>83</td>
<td>Only patients with liver metastasis</td>
</tr>
<tr>
<td>Capecitabine + TMZ</td>
<td>Phase II (2014)</td>
<td>28</td>
<td>11</td>
<td>32</td>
<td>54</td>
<td>&gt;20</td>
<td>NR</td>
<td>Abstract only</td>
</tr>
<tr>
<td>Capecitabine + TMZ</td>
<td>Retrospective (2011)</td>
<td>30</td>
<td>–</td>
<td>70</td>
<td>27</td>
<td>18</td>
<td>–</td>
<td>2-year OS: 92%; Only pancreatic NET</td>
</tr>
<tr>
<td>TMZ + Bev</td>
<td>Phase II (2012)</td>
<td>34</td>
<td>–</td>
<td>15</td>
<td>65</td>
<td>11</td>
<td>33.3</td>
<td>Most of the benefit seen in pancreatic NET</td>
</tr>
<tr>
<td>Pembrolizumab</td>
<td>Phase I KEYNOTE-028 (2020)</td>
<td>41</td>
<td>–</td>
<td>9.7</td>
<td>70.7</td>
<td>5.6/4.5*</td>
<td>–</td>
<td>PDL1 positive tumors only</td>
</tr>
<tr>
<td>Pembrolizumab</td>
<td>Phase II KEYNOTE -158 (2020)</td>
<td>107</td>
<td>–</td>
<td>3.7</td>
<td>56.1</td>
<td>4.1</td>
<td>24.2</td>
<td>All PR in PDL1 negative tumors</td>
</tr>
<tr>
<td>Ipilimumab + Nivolumab</td>
<td>Phase II DART SWOG 1609 (2020)</td>
<td>32</td>
<td>3</td>
<td>22</td>
<td>41</td>
<td>4</td>
<td>11</td>
<td>Only nonpancreatic NET, 56% NEC</td>
</tr>
</tbody>
</table>

Abbreviations: Bev, bevacizumab; CR, complete response; FOLFOX, FU with leucovorin plus oxaliplatin; CAPEOX, capecitabine plus oxaliplatin; NEC, neuroendocrine carcinoma; NET, neuroendocrine tumors; OS, overall survival; PDL1, programmed death ligand 1; PFS, progression-free survival; PR, partial response; SD, stable disease; STZ, streptozocin; TMZ, temozolomide.

*5.6 months for carcinoids and 4.5 months for pancreatic NET.

Indian Journal of Medical and Paediatric Oncology Vol. 42 No. 5/2021 © 2021. Indian Society of Medical and Paediatric Oncology. All rights reserved.
months with no complete response (CR) or partial response (PR).44

... She was then started on everolimus along with octreotide LAR and dose titrated to 10-mg daily. Two months later, she complained about worsening episodes of sweating, flushing, and dizziness, however, not associated with diarrhea or nausea. Blood work in clinic showed glucose levels of 43 which improved with oral glucose administration. Her abdominal pain and hip pain had improved and did not require any further opioid pain medications. Dietary education was given and continued having frequent laboratory checks.

It is important to understand the side-effect profile of each drug while choosing between two treatments. Although both everolimus and octreotide can inhibit insulin leading to hyperglycemia, especially in diabetic patients, both the drugs can cause paradoxical hypoglycemia by decreasing secretion of hormones for glycogenolysis and gluconeogenesis. SSAs are well tolerated with only one-third of patients developing mild symptoms of bloating, diarrhea, and nausea which improves with time.25 Use of pancreatic enzyme supplementation help resolve some symptoms.45 Also, 25% of patients may develop asymptomatic gallstones due to delayed gall bladder emptying. Equally important is to know the complications of SSA discontinuation, like carcinoid crisis, and long-term effects, like carcinoid heart syndrome, making it important to continue SSA beyond progression.

... 3 months later, Ga-68 DOTATATE scan demonstrated improvement in hepatic lesions but new areas of bone involvement including multiple vertebral bodies. She was started on PRRT. She tolerated the treatment well. Repeat Ga-68 DOTATATE scan after four doses of PRRT showed decreased avidity of skeletal lesions and no new lesions.

Case 2

A 52-year-old male initially presented with severe abdominal and back pain. CT showed multiple liver lesions. Fluorodeoxyglucose (FDG)-PET/CT confirmed hypermetabolic liver lesions, pancreatic cystic lesion, T11-L1 vertebral lesions, and portocaval lymphadenopathy. Biopsy of liver lesion showed G3 well-differentiated pancreatic NET with Ki-67 of 30%. He completed four cycles of cisplatin and etoposide which improved with oral glucose administration. Her abdominal pain and hip pain had improved and did not require any further opioid pain medications. Dietary education was given and continued having frequent laboratory checks.

Patients with advanced, well-differentiated G3 NETs do not often respond to platinum-etoposide regimen as with high-grade poorly differentiated NEC.50 Hence, treatment with carboplatin or cisplatin with etoposide is preferred only in very aggressive disease and on disease progression. Treatments used in low-to-intermediate grade NETs like capcitabine–temozolomide- or streptozocin-based chemotherapy or sunitinib is preferred as first-line therapy. Whenever possible, these patients should be encouraged to enroll in clinical trials as evidence is not clear due to exclusion of these patients from most of the clinical trials. ECOG-ACRIN EA2142 trial is currently evaluating capcitabine–temozolomide regimen versus cisplatin etoposide in NET G3 (ClinicalTrials.gov ID: NCT02595424). PRRT should be considered in NET G3 with high SSR uptake. Currently, no prospective data exist to support this, as this is extremely rare subset of NETs; however, presence of somatostatin receptor-2 (SSTR-2) makes PRRT a lucrative treatment option. Everolimus showed median progression free survival (mPFS) of 6 months and median overall survival (mOS) of 28 months after drug initiation in a series of 15 patients with NET G3.51 Most of the patients received it as second-line treatment and median Ki-67 was 30% in this study.

... Patient then received capcitabine plus temozolomide for 6 months. On disease progression, he was switched to everolimus. With SSR positivity on Ga-68 DOTATATE scan, patient was started on Lu-177 DOTATATE but progressed after four cycles. He was then initiated on sunitinib and due to intolerance, transitioned to off-label ipilimumab plus nivolumab.

Practical Recommendations

Following an evidence-based approach will provide maximum clinical benefit for patients without overt expenditure. Some of the practical recommendations are listed below:

- Indolent nature of the disease should be considered when choosing initial therapies. Observation and SSA analogs may be appropriate in asymptomatic stable disease.
- Blood-based biomarkers like chromogranin A have poor sensitivity and specificity.
- Baseline brain imaging is usually not required for staging. Multiphasic liver imaging and oral contrast for bowel evaluation can be done along with SSR-PET/CT in a single setting.
- Routine use of gallium-68-DOTATATE PET/CT for disease monitoring should be avoided. CT/MR are most reliable methods for radiological monitoring. FDG-PET should be used in NEC.
- There are indigenous SSR-directed PRRT therapeutics available in some low- to middle-income countries (LMICs) at a reduced cost, although no comparison on trials are available with standard product.52
- Networking with NET specialist for a second opinion and referring to consensus North American Neuroendocrine Tumor Society (NANETS) and European Society of Neuroendocrine Tumors (ENETS) guidelines is encouraged.
Conclusion

NETs are heterogeneous and rare tumors often posing challenging management dilemmas. A multidisciplinary approach is endorsed for their initial management. The discussion focused on medical management and a detailed analysis of the surgical modalities and nonsurgical procedures are outside the purview of this review. Due to the wide range of clinical behavior and treatment responses with NETs, treatment should always be individualized. Being a rare tumor with limited randomized controlled data available, clinical trial participation is encouraged. We recommend referring to the National Comprehensive Cancer Network (NCCN), NANETS, and ENETS guidelines for updated management options that may change as results from ongoing trials are published.

Financial Disclosures

Conflict of Interest
L.A. reports grants from Lexicon Pharmaceuticals, Inc., Entrinsic Health, Inc., and personal fees from Sun Pharmaceuticals, Inc., during the conduct of the study. A.C. reports grants from BMS, EMD Serono, Nanopharmaceuticals, and Clovis; other from Ipsen, Novartis, Lexicon, TerSera; and nonfinancial support from ECS Progastrin, during the conduct of the study. R.A.R. reports personal fees from Ipsen Biopharmaceuticals, Novartis, Curium, Advanced Accelerator Applications, Genentech, AstraZeneca, grants and personal fees from Merck, and grants from Aadi Bioscience, outside the submitted work.

References
14 Lesurtel M, Nagorney DM, Mazzaferrro V, Jensen RT, Poston GJ. When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? A systematic review with practice recommendations. HPB (Oxford 2015;17(01):17–22
22 Moris D, Tsilimigras DI, Ntanasis-Stathopoulos I, et al. Liver transplantation in patients with liver metastases from

Indian Journal of Medical and Paediatric Oncology Vol. 42 No. 5/2021 © 2021. Indian Society of Medical and Paediatric Oncology. All rights reserved.


32 Capdevila J, Fazio N, Lopez CL, et al. Final results of the TALENT trial (GETNE1509): a prospective multicohort phase II study of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (gINETs) neuroendocrine tumors (NETs. J Clin Oncol 2019;37(15suppl):4106


